Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-centre Trial of Alipogene Tiparvovec for the Treatment of LPLD Patients

Next Previous
Trial Profile

An Open Label, Multi-centre Trial of Alipogene Tiparvovec for the Treatment of LPLD Patients

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alipogene tiparvovec (Primary) ; Ciclosporin; Mycophenolate mofetil; Prednisolone
  • Indications Hyperlipoproteinaemia type I
  • Focus Therapeutic Use
  • Sponsors uniQure

    • Most Recent Events

    • 20 Jul 2017 Status changed from recruiting to withdrawn prior to enrolment because uniQure., has decided not to renew the Marketing Authorization of Glybera in the EU and this decision is not related to any safety, efficacy or quality issue .
    • 13 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 03 Oct 2016 Planned initiation date changed from 1 Sep 2016 to 1 Oct 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top